NCT03464435View on ClinicalTrials.gov

A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

November 1, 2017

Study Completion Date

February 1, 2018

Conditions
Vernal Keratoconjunctivitis
Interventions
DRUG

Tacrolimus

All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.

All Listed Sponsors
lead

Zhongshan Ophthalmic Center, Sun Yat-sen University

OTHER

NCT03464435 - A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis | Biotech Hunter | Biotech Hunter